Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 464 of the 465 references it cites were found in a registry or an index.

Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions

Open access
Chen, Zhou, Han, Fangfang, Du, Yan, Shi, Huaqing, Zhou, Wence · 2023 · Signal Transduction and Targeted Therapy

Abstract

Having a hypoxic microenvironment is a common and salient feature of most solid tumors. Hypoxia has a profound effect on the biological behavior and malignant phenotype of cancer cells, mediates the effects of cancer chemotherapy, radiotherapy, and immunotherapy through complex mechanisms, and is closely associated with poor prognosis in various cancer patients. Accumulating studies have demonstrated that through normalization of the tumor vasculature, nanoparticle carriers and biocarriers can effectively increase the oxygen concentration in the tumor microenvironment, improve drug delivery and the efficacy of radiotherapy. They also increase infiltration of innate and adaptive anti-tumor immune cells to enhance the efficacy of immunotherapy. Furthermore, drugs targeting key genes associated with hypoxia, including hypoxia tracers, hypoxia-activated prodrugs, and drugs targeting hypoxia-inducible factors and downstream targets, can be used for visualization and quantitative analysis of tumor hypoxia and antitumor activity. However, the relationship between hypoxia and cancer is an area of research that requires further exploration. Here, we investigated the potential factors in the development of hypoxia in cancer, changes in signaling pathways that occur in cancer cells to adapt to hypoxic environments, the mechanisms of hypoxia-induced cancer immune tolerance, chemotherapeutic tolerance, and enhanced radiation tolerance, as well as the insights and applications of hypoxia in cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01332-8

Cites

464 of 464 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A historical and chronological figure of major events in tumor hypoxia research
Fig. 1 A historical and chronological figure of major events in tumor hypoxia researchCC BY · PubMed Central
Fig. 2 Potential factors contributing to tumor hypoxia. Carcinogenic factors, such as drug, carcinogen, and microbiota dysbiosis, impair EC shape and function in the vascular system. TME is remodeled by tumor cells, stromal cells and stromal components (e.g., fibrin), resulting in vascular deformation due to pressure. High metabolism in cancer cells, such as increased nucleic acid synthesis and increased protein anabolism, leads to relative hypoxia. Dysregulated proliferation and alignment of vascular ECs result in the formation of non-functional blood vessels. With the increased distance between tumor cells and blood vessels, O2 diffusion decreases and leads to hypoxia
Fig. 2 Potential factors contributing to tumor hypoxia. Carcinogenic factors, such as drug, carcinogen, and microbiota dysbiosis, impair EC shape and function in the vascular system. TME is remodeled by tumor cells, stromal cells and stromal components (e.g., fibrin), resulting in vascular deformation due to pressure. High metabolism in cancer cells, such as increased nucleic acid synthesis and increased protein anabolism, leads to relative hypoxia. Dysregulated proliferation and alignment of vascular ECs result in the formation of non-functional blood vessels. With the increased distance between tumor cells and blood vessels, O2 diffusion decreases and leads to hypoxiaCC BY · PubMed Central
Fig. 3 Biological changes in cancer cells adapt to hypoxia. Hypoxia promotes carcinogenesis by inducing DNA strand breaks, including DNA DSB and SSB, and by weakening DNA repair pathways, such as HR and MMR. HIF-1α is upgraded by PI3K-mTOR, JAK-STAT3, NF-κB, MAPK, Wnt/β-catenin, and Notch pathway. Deletion of tumor suppressor genes, such as p53, PTEN, and ROS production, also contributes to the upregulation of HIF-1α. The loss of pVHL function under hypoxic conditions indirectly leads to HIF-1α accumulation. HIF-1α dimerizes with HIF-1β and enters the nucleus to bind to HRE, which regulates various downstream target genes (Table 1) to promote cancer cell proliferation, migration, invasion, EMT and angiogenesis
Fig. 3 Biological changes in cancer cells adapt to hypoxia. Hypoxia promotes carcinogenesis by inducing DNA strand breaks, including DNA DSB and SSB, and by weakening DNA repair pathways, such as HR and MMR. HIF-1α is upgraded by PI3K-mTOR, JAK-STAT3, NF-κB, MAPK, Wnt/β-catenin, and Notch pathway. Deletion of tumor suppressor genes, such as p53, PTEN, and ROS production, also contributes to the upregulation of HIF-1α. The loss of pVHL function under hypoxic conditions indirectly leads to HIF-1α accumulation. HIF-1α dimerizes with HIF-1β and enters the nucleus to bind to HRE, which regulates various downstream target genes (Table 1) to promote cancer cell proliferation, migration, invasion, EMT and angiogenesisCC BY · PubMed Central
Fig. 4 Glucose and lipid metabolism in cancer cells under hypoxic conditions. Glucose is taken up by cancer cells via GLUT1 and glycolysed to pyruvate via PKM, PGK1 and PGAM1. Hypoxic cancer cells promote pyruvate glycolysis to lactate by upregulating LDHA, LDHC and LDH-5, and the lactate produced is excreted outside the cell via MCT1/4. In addition, HIF-1α inactivates PDH by activating PDK1, which in turn fails to convert pyruvate to acetyl-CoA, preventing the entry of pyruvate into the TCA cycle. Cytoplasmic citrate is catalyzed by ALCY to acetyl-CoA, and acetyl-CoA catalyzed by ACC to malonyl-CoA. Acetyl-CoA and malonyl-CoA are catalyzed to FA via FASN upregulated by SREBP-1. SCD1 upregulated by SREBP-1 catalyzes the formation of MUFA from saturated FA. PHD3 loss reduces ACC2 hydroxylation and promotes FAO to provide energy. α-KG as a product of glutamine is reduced and carboxylated to isocitrate by IDH, and then oxidation to citrate. PLD hydrolyzes PC to produce PA. PLA2 catalyzes the hydrolysis of GPL to produce Lyso-PL
Fig. 4 Glucose and lipid metabolism in cancer cells under hypoxic conditions. Glucose is taken up by cancer cells via GLUT1 and glycolysed to pyruvate via PKM, PGK1 and PGAM1. Hypoxic cancer cells promote pyruvate glycolysis to lactate by upregulating LDHA, LDHC and LDH-5, and the lactate produced is excreted outside the cell via MCT1/4. In addition, HIF-1α inactivates PDH by activating PDK1, which in turn fails to convert pyruvate to acetyl-CoA, preventing the entry of pyruvate into the TCA cycle. Cytoplasmic citrate is catalyzed by ALCY to acetyl-CoA, and acetyl-CoA catalyzed by ACC to malonyl-CoA. Acetyl-CoA and malonyl-CoA are catalyzed to FA via FASN upregulated by SREBP-1. SCD1 upregulated by SREBP-1 catalyzes the formation of MUFA from saturated FA. PHD3 loss reduces ACC2 hydroxylation and promotes FAO to provide energy. α-KG as a product of glutamine is reduced and carboxylated to isocitrate by IDH, and then oxidation to citrate. PLD hydrolyzes PC to produce PA. PLA2 catalyzes the hydrolysis of GPL to produce Lyso-PLCC BY · PubMed Central
Fig. 5 Hypoxia remodels CTL immune effect. HIF-1α in CTL is upgraded by TCR-PKC and Ca2+/calcineurin, PI3K/mTOR, NF-κB, NF-κB, JAK-STAT3, MAPK pathway. Deletion of pVHL impaired HIF-1α degradation. HIF-1α and HIF-1β dimerization stimulates downstream factor expression, such as perforin, IFN-γ, TNF-α, which can enhance the antitumor efficacy of CTL. However, some experiments elaborate the opposite results. Hypoxia inhibits the expression of IFN-γ, TNF-α, granzyme B, IL-2, perforin and NKG2D, while promoting PD-L1,PD-1 and CTLA-4 expression. CTL increases glucose uptake via GLUT1, which is metabolized to lactate by glycolytic enzymes PK and LDH. Lactate acidifies the TME, which inhibits CTL activation
Fig. 5 Hypoxia remodels CTL immune effect. HIF-1α in CTL is upgraded by TCR-PKC and Ca2+/calcineurin, PI3K/mTOR, NF-κB, NF-κB, JAK-STAT3, MAPK pathway. Deletion of pVHL impaired HIF-1α degradation. HIF-1α and HIF-1β dimerization stimulates downstream factor expression, such as perforin, IFN-γ, TNF-α, which can enhance the antitumor efficacy of CTL. However, some experiments elaborate the opposite results. Hypoxia inhibits the expression of IFN-γ, TNF-α, granzyme B, IL-2, perforin and NKG2D, while promoting PD-L1,PD-1 and CTLA-4 expression. CTL increases glucose uptake via GLUT1, which is metabolized to lactate by glycolytic enzymes PK and LDH. Lactate acidifies the TME, which inhibits CTL activationCC BY · PubMed Central
Fig. 6 Changes in cytokine secretion by innate immune cells under hypoxic conditions. M1 microphage secretes iNOS, and M2 macrophages secrete IL-10, EGF, VEGF, MMP, DPD, PDGF and TGF-β to suppress immune responses. Lactate induces M2-like polarization. HIF-1α inhibits NK cell expression of perforin, NKG2D, GM-CSF, granzyme B and IFN-γ. Hypoxia induces neutrophils to produce ROS and NETs, which promote tumorigenesis and metastasis. HIF-1α induces MDSCs to secrete cytokines NO, arginase, PD-L1, RORA, PTEN, CD39, CD73 and S100A9, which inhibit immune response and promote the tumor cell stemness and growth. ILC1 secretes granzyme A and maintains antitumor efficacy. ILC2 enhances immune response through selective expression of CCL5, CXCR2. Hypoxia induces IL-10 expression in ILC2 and suppresses immunity. ILC3 secretes CXCL10 and IL-22, improving antitumor immune response
Fig. 6 Changes in cytokine secretion by innate immune cells under hypoxic conditions. M1 microphage secretes iNOS, and M2 macrophages secrete IL-10, EGF, VEGF, MMP, DPD, PDGF and TGF-β to suppress immune responses. Lactate induces M2-like polarization. HIF-1α inhibits NK cell expression of perforin, NKG2D, GM-CSF, granzyme B and IFN-γ. Hypoxia induces neutrophils to produce ROS and NETs, which promote tumorigenesis and metastasis. HIF-1α induces MDSCs to secrete cytokines NO, arginase, PD-L1, RORA, PTEN, CD39, CD73 and S100A9, which inhibit immune response and promote the tumor cell stemness and growth. ILC1 secretes granzyme A and maintains antitumor efficacy. ILC2 enhances immune response through selective expression of CCL5, CXCR2. Hypoxia induces IL-10 expression in ILC2 and suppresses immunity. ILC3 secretes CXCL10 and IL-22, improving antitumor immune responseCC BY · PubMed Central
Fig. 7 Hypoxia enhances tumor chemotherapy resistance. IL-6 stimulates HIF-1α expression, which increases PGP expression through upregulation of miR-27a. Chemotherapeutic agents are transported by HIF-1α-induced intracellular MRP1 and excreted from cells via PGP and BCRP. HIF-1α induces OLFM4 to enhance cancer cell chemoresistance. HIF-1α enhances chemotherapeutic resistance in cancer cells by promoting PKM1, enhancing mitochondrial OXPHOS. Under hypoxic conditions, cancer cells induce enhanced autophagy and inhibit the chemotherapeutic drug-induced BNIP3 death pathway to resist drug toxicity. HIF-1α synergizes with TGF-β to promote GLI2 expression through SMAD3, inducing cancer cell stemness and chemoresistance. HIF-2α upregulation promotes the ability of hypoxic cancer cells to resist drug toxicity by activating the TGF-α/EGFR pathway and COX-2. In addition, CDD and SLC play important roles in the drug resistance of cancer cells, the effect of hypoxic conditions on CDD and SLC is unclear
Fig. 7 Hypoxia enhances tumor chemotherapy resistance. IL-6 stimulates HIF-1α expression, which increases PGP expression through upregulation of miR-27a. Chemotherapeutic agents are transported by HIF-1α-induced intracellular MRP1 and excreted from cells via PGP and BCRP. HIF-1α induces OLFM4 to enhance cancer cell chemoresistance. HIF-1α enhances chemotherapeutic resistance in cancer cells by promoting PKM1, enhancing mitochondrial OXPHOS. Under hypoxic conditions, cancer cells induce enhanced autophagy and inhibit the chemotherapeutic drug-induced BNIP3 death pathway to resist drug toxicity. HIF-1α synergizes with TGF-β to promote GLI2 expression through SMAD3, inducing cancer cell stemness and chemoresistance. HIF-2α upregulation promotes the ability of hypoxic cancer cells to resist drug toxicity by activating the TGF-α/EGFR pathway and COX-2. In addition, CDD and SLC play important roles in the drug resistance of cancer cells, the effect of hypoxic conditions on CDD and SLC is unclearCC BY · PubMed Central
Fig. 8 Hypoxia enhances the ability of the tumor to resist radiotherapy. Radiotherapy induces cancer cell death by directly damaging DNA through the production of free radicals such as OH• and H•. SPINK1, secreted by hypoxic cancer cells, upregulates EGFR and NRF2 antioxidant response in adjacent cancer cells to reduce radiation-induced DNA damage, thereby inducing cancer radioresistance. VEGF, FGF and PDGF secreted by hypoxic cancer cells enhanced the radiation resistance of ECs. HIF-1α stimulates DNA-PK expression and repairs DNA DSB
Fig. 8 Hypoxia enhances the ability of the tumor to resist radiotherapy. Radiotherapy induces cancer cell death by directly damaging DNA through the production of free radicals such as OH• and H•. SPINK1, secreted by hypoxic cancer cells, upregulates EGFR and NRF2 antioxidant response in adjacent cancer cells to reduce radiation-induced DNA damage, thereby inducing cancer radioresistance. VEGF, FGF and PDGF secreted by hypoxic cancer cells enhanced the radiation resistance of ECs. HIF-1α stimulates DNA-PK expression and repairs DNA DSBCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 465 references

Cited by

See all 1,612

Metadata

Authors
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W.
Affiliations
  • First Hospital of Lanzhou University (CN)
  • Lanzhou University Second Hospital (CN)
Corresponding author
Zhou, Wence
Venue
Signal Transduction and Targeted Therapy
Published
2023-02-17
Volume
8
Issue
1
Pages
70-70
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4321167021
Cited by
1,612
References
465
Citations by year
2026: 574 · 2025: 662 · 2024: 326 · 2023: 48
FWCI
50.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Lanzhou University (ldyyyn2020-93)
  • National Natural Science Foundation of China (82260555)
  • Natural Science Foundation of Gansu Province (82260555, 22JR11RA033)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
tumor hypoxia, tumor microenvironment, hypoxia-inducible factor, hypoxia signaling pathway, tumor vasculature normalization, nanoparticle drug delivery, hypoxia-activated prodrug, cancer immunotherapy, radiotherapy resistance, chemoresistance, tumor immune tolerance
MeSH terms
Hypoxia, Humans, Immunotherapy, Neoplasms, Radiation Tolerance, Cell Hypoxia, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. https://app.cochat.ai/papers/10.1038/s41392-023-01332-8
The paper
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023). Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01332-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.